1,089 results

#187180-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSyn1_nLightR (#187180). In addition to the viral particles, you will also receive purified pAAV_hSyn1_nLightR plasmid DNA. Syn-driven expression of red norepinephrine sensor nLightR. These AAV preparations are suitable purity for injection into animals.

Tommaso Patriarchi

Kagiampaki et al Nat Methods. 2023 Sep;20(9):1426-1436. d

June 21, 2024

Academic Institutions and Nonprofits only

#121675-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2023

Academic Institutions and Nonprofits only

#83898-AAV1

Ready-to-use AAV1 particles produced from pAAV-mDlx-ChR2-mCherry-Fishell-3 (#83898). In addition to the viral particles, you will also receive purified pAAV-mDlx-ChR2-mCherry-Fishell-3 plasmid DNA. mDlx-driven expression of ChR2, fused to mCherry. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 9, 2020

Academic Institutions and Nonprofits only

#100054-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 (#100054). In addition to the viral particles, you will also receive purified pAAV.CAG.hChR2(H134R)-mCherry.WPRE.SV40 plasmid DNA. CAG-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 7, 2020

Academic Institutions and Nonprofits only

#218877-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#37825-CAP-B22

Ready-to-use AAV CAP-B22 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B22 serotype, which permits efficient transduction of neurons and astrocytes in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#104492-AAV9

Ready-to-use AAV9 particles produced from pGP-AAV-syn-FLEX-jGCaMP7f-WPRE (#104492). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7f-WPRE plasmid DNA. Syn-driven, Cre-dependent GCaMP7f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Aug. 6, 2018

Academic Institutions and Nonprofits only

#137122-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-Con/Fon-GCaMP6F (#137122). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-GCaMP6F plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

July 17, 2020

Academic Institutions and Nonprofits only

#114469-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CaMKIIa-mCherry (#114469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mCherry plasmid DNA. CamKIIa-driven expression of mCherry. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#51084-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-hSyn1-GCaMP6s-P2A-nls-dTomato (#51084). In addition to the viral particles, you will also receive purified AAV-hSyn1-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under a human synapsin1 promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

June 21, 2017

Academic Institutions and Nonprofits only

#26971-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-eNpHR 3.0-EYFP (#26971). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-eNpHR 3.0-EYFP plasmid DNA. CaMKIIa-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 14, 2018

Academic Institutions and Nonprofits only

#105545-AAV8

Ready-to-use AAV8 particles produced from pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 (#105545). In addition to the viral particles, you will also receive purified pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. CMV-driven EGFP-Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#176753-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8f-WPRE (#176753). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8f-WPRE plasmid DNA. mDlx-driven expression of ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#98747-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#51507-AAV5

Ready-to-use AAV5 particles produced from AAV pmSyn1-EBFP-Cre (#51507). In addition to the viral particles, you will also receive purified AAV pmSyn1-EBFP-Cre plasmid DNA. EBFP-Cre expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Oct. 30, 2017

Academic Institutions and Nonprofits only

#178331-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.GPI (#178331). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.GPI plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only

#213936-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#105530-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Feb. 16, 2024

Academic Institutions and Nonprofits only

#183535-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-Flpo (#183535). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-Flpo plasmid DNA. CamKIIa-driven expression of Flpo recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fan et al Cell. 2023 Feb 2;186(3):543-559.e19. doi

Oct. 8, 2025

Academic Institutions and Nonprofits only

#106174-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S, glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

June 20, 2018

Academic Institutions and Nonprofits only

#232352-AAV5

Ready-to-use AAV5 particles produced from pAAV-DIO-ATLASsnFlp (#232352). In addition to the viral particles, you will also receive purified pAAV-DIO-ATLASsnFlp plasmid DNA. Syn-driven, ATLASsnFlp expression. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Rivera et al Nat Methods. 2025 May;22(5):1101-1111. d

Jan. 14, 2026

Academic Institutions and Nonprofits only

#50472-AAV5

Ready-to-use AAV5 particles produced from pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine (#50472). In addition to the viral particles, you will also receive purified pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine plasmid DNA. GFAP-driven HA-tagged rM3D(Gs) and bicistronic mCitrine expression, for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#176755-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8s-WPRE (#176755). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8s-WPRE plasmid DNA. mDlx-driven expression of the calcium sensor jGCaMP8s in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Sept. 12, 2023

Academic Institutions and Nonprofits only

#176754-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8m-WPRE (#176754). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8m-WPRE plasmid DNA. mDlx enhancer-driven expression of calcium sensor GCaMP8m in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#52473-AAV1

Ready-to-use AAV1 particles produced from pAAV-synP-FLEX-splitTVA-EGFP-B19G (#52473). In addition to the viral particles, you will also receive purified pAAV-synP-FLEX-splitTVA-EGFP-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Kohara et al Nat Neurosci. 2014 Feb;17(2):269-79. doi

Dec. 18, 2018

Academic Institutions and Nonprofits only

#154948-AAV5

Ready-to-use AAV5 particles produced from CaMKII-somBiPOLES-mCerulean (#154948). In addition to the viral particles, you will also receive purified CaMKII-somBiPOLES-mCerulean plasmid DNA. CamKII-driven expression of soma-targeted BiPOLES for optogenetic inhibition (blue light) and activation (red light). These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Vierock et al Nat Commun. 2021 Jul 26;12(1):4527. doi:

Sept. 1, 2021

Academic Institutions and Nonprofits only

#163909-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSynapsin_psychLight2 (#163909). In addition to the viral particles, you will also receive purified pAAV_hSynapsin_psychLight2 plasmid DNA. Synapsin-driven expression of the genetically encoded fluorescent sensor psychLight2 to detect behaviorally relevant serotonin release. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Dong et al Cell. 2021 Apr 8. pii: S0092-8674(21)003

Feb. 16, 2024

Academic Institutions and Nonprofits only

#55641-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 25, 2021

Academic Institutions and Nonprofits only

#51502-AAV2

Ready-to-use AAV2 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

March 7, 2018

Academic Institutions and Nonprofits only

#213941-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_ChR2_mCherry (#213941). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#176750-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CamKIIa-jGCaMP8f-WPRE (#176750). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8f-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 21, 2023

Academic Institutions and Nonprofits only

#51085-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn1-GCaMP6f-P2A-nls-dTomato (#51085). In addition to the viral particles, you will also receive purified AAV-hSyn1-GCaMP6f-P2A-nls-dTomato plasmid DNA. GCaMP6f calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Sept. 21, 2017

Academic Institutions and Nonprofits only

#197200-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-emiRFP670 (#197200). In addition to the viral particles, you will also receive purified pAAV-CAG-emiRFP670 plasmid DNA. CAG-driven expression of emiRFP670. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhang et al Nat Methods. 2023 Sep 4. doi: 10.1038/s4

Feb. 7, 2025

Academic Institutions and Nonprofits only

#84446-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

March 18, 2024

Academic Institutions and Nonprofits only

#26966-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

March 27, 2024

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#135632-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-GCaMP6f (#135632). In addition to the viral particles, you will also receive purified pAAV-S5E2-GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 11, 2020

Academic Institutions and Nonprofits only

#45185-AAV9

Ready-to-use AAV9 particles produced from AAV-EF1a-BbTagBY (#45185). In addition to the viral particles, you will also receive purified AAV-EF1a-BbTagBY plasmid DNA. Brainbow construct encoding farnesylated TagBFP and EYFP, both in reverse orientation between mutant Lox sites. These AAV preparations are suitable purity for injection into animals.

Dawen Cai, Joshua Sanes

Cai et al Nat Methods. 2013 May 5;10(6):540-7. doi

March 7, 2018

Academic Institutions and Nonprofits only

#84446-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

June 21, 2024

Academic Institutions and Nonprofits only

#105537-AAV8

Ready-to-use AAV8 particles produced from pENN.AAV.CMVs.Pl.Cre.rBG (#105537). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.Pl.Cre.rBG plasmid DNA. CMV-driven Cre. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Dec. 14, 2018

Academic Institutions and Nonprofits only

#104488-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-jGCaMP7f-WPRE (#104488). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7f-WPRE plasmid DNA. Synapsin-driven GCaMP7f calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Feb. 23, 2018

Academic Institutions and Nonprofits only

#158757-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-SomaGCaMP6f2 (#158757). In addition to the viral particles, you will also receive purified pAAV-CAG-SomaGCaMP6f2 plasmid DNA. CAG-driven expression of soma-targeting GCaMP6f2. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Neuron. 2020 Jun 26. pii: S0896-6273(20)

Jan. 6, 2022

Academic Institutions and Nonprofits only

#162377-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-FLEX-jGCaMP8s-WPRE (#162377). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP8s-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of calcium sensor GCaMP8s (more sensitive). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

June 22, 2021

Academic Institutions and Nonprofits only

#105669-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#137163-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#179464-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-JEDI-2P-WPRE (#179464). In addition to the viral particles, you will also receive purified pAAV-hSyn-JEDI-2P-WPRE plasmid DNA. hSyn-driven expression of the genetically encoded voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Jan. 24, 2024

Academic Institutions and Nonprofits only

#214853-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14035: pAAV-AiE0452h_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4035) (#214853). In addition to the viral particles, you will also receive purified AiP14035: pAAV-AiE0452h_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4035) plasmid DNA. minBG-driven expression of CoChR-EGFP striatal indirect pathway medium spiny neurons (D2 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#50477-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hM4D(Gi)-mCherry (#50477). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM4D(Gi)-mCherry plasmid DNA. CaMKIIa-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Dec. 18, 2024

Academic Institutions and Nonprofits only